Yizun Medicine Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $13.9M

  • Investors
  • 14

Yizun Medicine General Information

Description

Developer of cell therapy designed for solid tumors. The company focuses on research and development on solid tumor treatment and allogeneic cells and is accelerating the development of allogeneic cell drugs for the treatment of advanced liver cancer, proving patients with innovative immune cell therapy technologies and products.

Contact Information

Formerly Known As
Yizun Biopharmaceutical (Shanghai) Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 208, 2nd Floor, Building 1/2
  • Number 658 Bin'an Road, Binjiang District
  • Hangzhou, Zhejiang 310051
  • China
+86 173
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Room 208, 2nd Floor, Building 1/2
  • Number 658 Bin'an Road, Binjiang District
  • Hangzhou, Zhejiang 310051
  • China
+86 173

Yizun Medicine Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Yizun Medicine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A1) 15-Apr-2024 $13.9M Completed Generating Revenue
5. Secondary Transaction - Private 28-Feb-2023 Completed Generating Revenue
4. Early Stage VC (Series A) 05-Jan-2022 Completed Generating Revenue
3. Early Stage VC 05-Jun-2019 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 13-Apr-2018 Completed Startup
To view Yizun Medicine’s complete valuation and funding history, request access »

Yizun Medicine Patents

Yizun Medicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026153328-A1 Chimeric receptor complex based on transmembrane structure of nkg2d Pending 14-Jan-2025
WO-2026002282-A1 Nanobodies targeting and/or specifically binding to b7-h3 Pending 28-Jun-2024
JP-2026531351-A Modified cells and their use Pending 03-Aug-2023
AU-2024318322-A1 Modified cells and uses thereof Pending 03-Aug-2023
EP-4754241-A1 Modified cells and uses thereof Pending 03-Aug-2023 C12N5/0636
To view Yizun Medicine’s complete patent history, request access »

Yizun Medicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Yizun Medicine Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hangzhou Hi-Tech Financial Investment Group Venture Capital Minority
Hangzhou Tailong Venture Capital Partnership Growth/Expansion Minority
TigerYeah Capital Venture Capital Minority
Angel (individual) Minority
Shenzhen Chongshi Private Equity Investment Fund Management PE/Buyout Minority
You’re viewing 5 of 14 investors. Get the full list »

Yizun Medicine FAQs

  • When was Yizun Medicine founded?

    Yizun Medicine was founded in 2018.

  • Where is Yizun Medicine headquartered?

    Yizun Medicine is headquartered in Hangzhou, China.

  • What is the size of Yizun Medicine?

    Yizun Medicine has 20 total employees.

  • What industry is Yizun Medicine in?

    Yizun Medicine’s primary industry is Drug Discovery.

  • Is Yizun Medicine a private or public company?

    Yizun Medicine is a Private company.

  • What is Yizun Medicine’s current revenue?

    The current revenue for Yizun Medicine is .

  • How much funding has Yizun Medicine raised over time?

    Yizun Medicine has raised $18.2M.

  • Who are Yizun Medicine’s investors?

    Hangzhou Hi-Tech Financial Investment Group, Hangzhou Tailong Venture Capital Partnership, TigerYeah Capital, , and Shenzhen Chongshi Private Equity Investment Fund Management are 5 of 14 investors who have invested in Yizun Medicine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process